



KemPharm to Report First Quarter 2021 Results

May 6, 2021 8:30 PM EDT

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 13, 2021, 4:30 p.m. ET

CELEBRATION, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, May 13, 2021, at 4:30 p.m. ET, to discuss its corporate and financial results for the first quarter 2021.

Conference Call Information:

Interested participants and investors may access the conference call by dialing either:

- (866) 395-2480 (U.S.)
- (678) 509-7538 (international)
- Conference ID: 4737008

An audio webcast with slide presentation will be accessible via the Investor Relations section of the Company's website, <http://investors.kempharm.com/>. An archive of the webcast and presentation will be available for 90 days beginning at approximately 5:30 p.m. ET, on May 13, 2021.

Investors may submit questions to KemPharm prior to the First Quarter 2021 Results conference call by e-mail to mmcenroe@tiberend.com. Please use the e-mail subject heading "KemPharm First Quarter 2021 Question" to ensure that the information is received. KemPharm's management will then respond to select questions during the conference call.

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT[®] (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT[®] technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) and CNS rare diseases, including idiopathic hypersomnia (IH). KemPharm's lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate (SDX). In addition, KemPharm has received FDA approval for AZSTARYS[™], a new once-daily treatment for ADHD in patients age six years and older, and for APADA[®], an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

KemPharm Contacts:

Jason Rando / Maureen McEnroe
Tiberend Strategic Advisors, Inc.
(212) 375-2665 / 2664
jrando@tiberend.com
mmcenroe@tiberend.com



Source: KemPharm